The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies.
The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies.
复制标题
DOI：
10.3389/fgene.2013.00150
复制
发表时间：
2013
影响因子：
3.7
通讯作者：
Hill AF
中科院分区：
文献类型：
--
作者：
Cheng L;Quek CY;Sun X;Bellingham SA;Hill AF
神经退行性疾病如阿尔茨海默病（AD）的诊断工具目前包括主观神经心理学测试和专门的脑成像技术。虽然明确的诊断需要尸检时对大脑进行病理评估，但神经退行性改变被认为在认知能力下降的临床表现出现前几年就开始了。因此，非常需要可靠的生物标志物来帮助疾病的早期发现，以便实施预防策略。microRNAs （miRNA）是参与转录后基因调控的小的非编码RNA物种。mirna的表达水平具有作为诊断性生物标志物的潜力，因为它们可以在血浆、脑脊液和尿液等多种体液中循环，并且可以识别出组织特异性谱。深度测序技术的最新发展为开发生物标志物发现管道提供了一种可行的方法，以分析神经退行性疾病特异性体液中的miRNA特征。在这里，我们回顾了miRNA深度测序在生物液体生物标志物鉴定中的潜在应用及其在临床实践中的转化。
Diagnostic tools for neurodegenerative diseases such as Alzheimer's disease (AD) currently involve subjective neuropsychological testing and specialized brain imaging techniques. While definitive diagnosis requires a pathological brain evaluation at autopsy, neurodegenerative changes are believed to begin years before the clinical presentation of cognitive decline. Therefore, there is an essential need for reliable biomarkers to aid in the early detection of disease in order to implement preventative strategies. microRNAs (miRNA) are small non-coding RNA species that are involved in post-transcriptional gene regulation. Expression levels of miRNAs have potential as diagnostic biomarkers as they are known to circulate and tissue specific profiles can be identified in a number of bodily fluids such as plasma, CSF and urine. Recent developments in deep sequencing technology present a viable approach to develop biomarker discovery pipelines in order to profile miRNA signatures in bodily fluids specific to neurodegenerative diseases. Here we review the potential use of miRNA deep sequencing in biomarker identification from biological fluids and its translation into clinical practice.